United-Guardian, Inc. — Q1 2016 Form 10-Q
Business context and period: The company develops, manufactures, and markets cosmetic and personal-care ingredients, pharmaceutical and medical products, and specialty industrial products through its Guardian Laboratories division. This unaudited report covers the three months ended March 31, 2016, compared with the same period in 2015.
Financial performance
| Metric | Q1 2016 | Q1 2015 / comparison |
|---|---|---|
| Net sales | $2.263 million | $4.372 million; down 48.3% |
| Gross profit / gross margin | $1.365 million / 60.3% | $2.693 million / 61.6% |
| Income from operations / operating margin | $720,000 / 31.8% | $2.066 million / 47.2% |
| Net income / net margin | $525,000 / 23.2% | $1.461 million / 33.4% |
| Diluted and basic EPS | $0.11 | $0.32 |
| Operating cash flow | $743,000 | $1.810 million |
Cost of sales was 39.7% of sales, versus 38.4% a year earlier. Operating expenses rose 1.4% to $468,000; research and development expenses rose 6.8% to $178,000. Investment income declined 19.0% to $43,000, including a $10,180 realized investment loss. The effective tax rate was approximately 31% in both periods.
At March 31, 2016, cash and cash equivalents were $1.261 million and marketable securities were $11.417 million. Current assets were $15.940 million against current liabilities of $1.697 million; working capital was $14.243 million and the reported current ratio was 9.4:1. Total assets were $17.073 million and stockholders’ equity was $15.207 million. The balance sheet reports no borrowings or other debt. Cash increased by $181,000 during the quarter; investing activities used $563,000, principally for net purchases of marketable securities. There was no financing cash flow.
Material changes and management commentary
- Personal-care sales fell $2.376 million, or 68.7%, mainly because ASI reduced purchases of a LUBRAJEL product for China. Customer forecasts had been overly optimistic, and Chinese regulatory restrictions on certain cosmetics containing LUBRAJEL curtailed demand. ASI was drawing down previously accumulated inventory.
- Management said ASI purchases could resume gradually based on current forecasts, but were unlikely to be significant until at least Q3 2016. The company plans to work with ASI to rebuild sales and assess pricing as needed.
- Pharmaceutical sales increased 24.3%, including a 28.9% increase in RENACIDIN sales, though RENACIDIN remained below historical levels following prior manufacturing curtailments. The FDA approved a new single-dose 30 mL bottle in December 2015; sales in the new package began March 31, 2016. Management expects awareness and sales to build gradually.
- Medical-product sales increased 29.1%, which management attributed primarily to order timing and customer ordering patterns. Industrial and other product sales increased 83.5% from a comparatively smaller base.
- Gross margin declined mainly because sales shifted away from higher-margin LUBRAJEL and toward lower-margin, third-party-manufactured RENACIDIN. Management noted lower-priced imitations in Europe and Asia, a strong U.S. dollar, and continuing economic weakness in Europe; selective price reductions have affected margins and may continue.
Liquidity, outlook, and risks
Management believes working capital is sufficient for operating needs for at least the next 12 months and does not expect significant capital expenditures for the rest of 2016. It expects operating expenses to remain relatively consistent and the effective tax rate to remain near 31%. The company expects to use cash for dividends, marketable-security purchases, and other opportunities it considers beneficial to shareholders. These are management expectations, not guarantees.
Key disclosed risks include customer demand and order timing, dependence on marketing partners (ASI is the largest-volume partner), competition from lower-priced imitations, currency and economic conditions in Europe, product development and market acceptance, regulatory changes, and securities-market and interest-rate conditions. The company reported no off-balance-sheet arrangements and no legal proceedings. Disclosure controls were assessed as effective; no material change in internal control over financial reporting was reported.
Investor verification points
- Track ASI’s inventory drawdown and whether China-related LUBRAJEL orders resume as anticipated from Q3 2016.
- Assess whether RENACIDIN’s new packaging and marketing translate into sustained sales growth and whether supply remains reliable.
- Monitor sales mix, pricing pressure, and gross margins, particularly in Europe and Asia.
- Review operating cash generation and working-capital movements, including the increases in receivables, inventory, payables, and accrued expenses.
- Monitor the value and composition of the $11.417 million marketable-securities portfolio and related realized and unrealized gains or losses.